TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer

BACKGROUND: In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is associated with estrogen-independent tumor growth and resistance to endocrine therapies. This study investigated whether the addition of bevacizumab, a monocl...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Breast Cancer Res
Auteurs principaux: Vaklavas, Christos, Roberts, Brian S., Varley, Katherine E., Lin, Nancy U., Liu, Minetta C., Rugo, Hope S., Puhalla, Shannon, Nanda, Rita, Storniolo, Anna Maria, Carey, Lisa A., Saleh, Mansoor N., Li, Yufeng, Delossantos, Jennifer F., Grizzle, William E., LoBuglio, Albert F., Myers, Richard M., Forero-Torres, Andres
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2020
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7027068/
https://ncbi.nlm.nih.gov/pubmed/32070401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-020-01258-x
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires